Correction to: Scientific reports https://doi.org/10.1038/s41598-021-90497-9, published online 26 May 2021
The original version of this Article contained errors.
Olaf Kinzel was omitted from the author list in the original version of this Article.
In addition, the Acknowledgments section now reads:
“We thank members of Immunology Discovery, Discovery Sciences and Clinical Development teams in Janssen Research and Development, LLC and members in Phenex Pharmaceuticals AG for contributions and support of this work. We especially thank Tinghua Cao, Marciano Sablad, Monika Banaszewska, and Thomas Schlueter for performing or coordinating some biological assays. We thank Tony Greway and William Barchuk for clinical study discussions.”
Furthermore, the Author Contributions section now reads:
“X.X. supervised biology studies and wrote the manuscript. A.D.-T., R.L.-R., and G.C. performed biology experiments. M.A. coordinated biology experiments and performed some data analysis. F.S. supervised 1-month toleration studies. S.D. supervised clinical PD assay. D.D. and T.W. modeled human PK/PD and doses. S.G. and O.K. supervised medicinal and synthetic chemistry work. T.H. coordinated in vivo study. R.L.T. led clinical study. X.X., F.S., S.D., D.D., T.W., S.G. and R.L.T. were involved in the clinical study design. F.S., S.D., D.D., T.W., S.G. A.M.F. and R.L.T. contributed to writing manuscript. All authors reviewed the manuscript.”
Finally, the original version of this Article contained an error in Figure 1 where the structure of the compound JNJ-61803534 was drawn with the incorrect methyl stereochemistry on the pyrrolidine ring in panel (a). The original Figure 1 and accompanying legend appear below.
Structure and selectivity of JNJ-61803534 for inhibition of RORγt-driven transcription. (a) Structure of JNJ-61803534. (b) Activity of JNJ-61803534 in 1-hybrid reporter assays. HEK-293 T cells were transfected with vectors encoding RORγt, RORα or RORβ, respectively, fused with the GAL4 DNA binding domain. After incubation with compound overnight, luciferase signals were measured. JNJ-61803534 was tested at a starting concentration of 2 μM in three-fold serial dilutions in duplicate.
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Xue, X., De Leon-Tabaldo, A., Luna-Roman, R. et al. Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534. Sci Rep 12, 5740 (2022). https://doi.org/10.1038/s41598-022-09558-2
Published:
DOI: https://doi.org/10.1038/s41598-022-09558-2
